The two GLP-1 medications you’ll hear about most are semaglutide (sold as Ozempic for type 2 diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss). They’re both weekly injections. Both are expensive. Both reduce appetite and blood sugar. But they work through different mechanisms, and the head-to-head data shows real differences in outcomes worth knowing about.
Here’s what the head-to-head evidence shows.
The key mechanism difference
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that slows gastric emptying, stimulates insulin release, and reduces appetite by acting on brain receptors.
Tirzepatide is a dual agonist. It hits the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone involved in insulin regulation and fat storage. By hitting both receptors, tirzepatide appears to produce a larger metabolic effect than GLP-1 alone.
The weight loss data
The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, tested tirzepatide at three doses in people with obesity but without type 2 diabetes. The results were striking: at the highest dose (15 mg), participants lost an average of 22.5% of body weight over 72 weeks. At 10 mg, the average was 21.4%.
For comparison, the STEP-1 trial for semaglutide (2.4 mg weekly for weight loss) showed an average weight loss of 14.9% over 68 weeks.
These aren’t the same trials and shouldn’t be directly compared as if they were the same experiment. But a head-to-head trial — the SURMOUNT-5 study — did compare the two directly. Results published in 2025 showed tirzepatide produced roughly 20% more weight loss than semaglutide over the same period.
For blood sugar control in people with type 2 diabetes, tirzepatide also showed a larger A1C reduction in the SURPASS trials — an average reduction of about 2.1% at the highest dose, compared to approximately 1.5% for semaglutide in its trials.
Side effects: largely similar, with some differences
Both medications cause nausea, vomiting, diarrhea, and constipation, particularly in the early weeks of dose escalation. The GI side effect profile is similar between the two.
Tirzepatide may have a slightly lower rate of nausea than semaglutide in some analyses, though this varies across studies and may relate to how doses are escalated. Heart rate elevation, which is a known effect of semaglutide, appears to be less pronounced with tirzepatide.
Both carry a warning about thyroid tumors based on animal studies, and neither should be used by people with a personal or family history of medullary thyroid cancer or MEN2 syndrome.
Cost and access
Both medications are expensive without insurance — in the range of $900–$1,300 per month for the branded versions. Insurance coverage varies significantly, and coverage for weight loss specifically is less common than coverage for diabetes management.
Compounded versions of semaglutide became widely available during FDA-declared shortages; compounded tirzepatide has been more restricted. The shortage landscape changes frequently, so it’s worth checking current availability with a prescribing telehealth provider if cost is a barrier.
Which one makes more sense for you
The available evidence suggests tirzepatide produces somewhat larger effects on both weight loss and blood sugar control than semaglutide. That doesn’t mean tirzepatide is the right choice for everyone — individual response varies, insurance coverage matters, and both drugs are effective. If you’re discussing options with a physician, these comparisons are worth having in hand.
This content is for educational purposes only and is not medical advice. Consult your healthcare provider before making changes to your diet, supplements, or medications.
